Proudman K E, McMillan R M
Bioscience I Department, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
Agents Actions. 1991 Sep;34(1-2):121-4. doi: 10.1007/BF01993255.
Tolfenamic acid and tenidap have been reported to be dual inhibitors of cyclo-oxygenase and 5-lipoxygenase. In this study inhibition of 5-lipoxygenase by tenidap and tolfenamic acid in plasma-free leukocyte suspensions (IC50 values = 10 microM) required concentrations more than 100 fold higher than those which inhibited cyclo-oxygenase (IC50 values = 0.05 and 0.02 microM respectively). The potencies of tolfenamic acid and tenidap as cyclo-oxygenase inhibitors were markedly reduced in blood (IC50 = 6.5 and 10 microM respectively) and neither significantly inhibited 5-lipoxygenase. Since both drugs also failed to inhibit 5-lipoxygenase in rat blood ex vivo, we conclude that, at physiological levels of plasma proteins, tolfenamic acid and tenidap are selective cyclo-oxygenase inhibitors.
据报道,托芬那酸和替硝唑是环氧化酶和5-脂氧合酶的双重抑制剂。在本研究中,在无血浆的白细胞悬液中,替硝唑和托芬那酸对5-脂氧合酶的抑制作用(IC50值 = 10微摩尔)所需浓度比抑制环氧化酶的浓度高出100多倍(IC50值分别为0.05和0.02微摩尔)。在血液中,托芬那酸和替硝唑作为环氧化酶抑制剂的效力显著降低(IC50分别为6.5和10微摩尔),且两者均未显著抑制5-脂氧合酶。由于这两种药物在离体大鼠血液中也未能抑制5-脂氧合酶,我们得出结论,在血浆蛋白的生理水平下,托芬那酸和替硝唑是选择性环氧化酶抑制剂。